Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Medications › FOLFIRI

FOLFIRI

1 published article · Updated continuously

Clinical Trial Landscape

Clinical Trials of FOLFIRI

18 trials tracked of FOLFIRI: 4 in phase 3 or 4 and 3 with published results. The most-cited published study has 2934 citations.

18Trials tracked
4Phase 3 & 4
0Recruiting
3With published results
Phase distribution
Phase 3 4 Phase 2 12 Phase 1 2
  1. Phase 3 Study of Pembrolizumab (MK-3475) vs Standard Therapy in Participants With Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Stage IV Colorectal Carcinoma (MK-3475-177/KEYNOTE-177) Completed · 2,934 cited
  2. Phase 3 Cetuximab and/or Bevacizumab Combined With Combination Chemotherapy in Treating Patients With Metastatic Colorectal Cancer Completed · 64 cited
  3. Phase 3 Safety and Quality of Life Study of Aflibercept in Patients With Metastatic Colorectal Cancer Previously Treated With an Oxaliplatin-Based Regimen Completed · 19 cited
  4. Phase 3 Comparison of Treatment Effect of Chemotherapy With Panitumumab to Chemotherapy Alone Completed
  5. Phase 2 Study Comparing Veliparib Plus FOLFIRI Versus Placebo Plus FOLFIRI With or Without Bevacizumab in Previously Untreated Metastatic Colorectal Cancer Completed
  6. Phase 2 A Phase II, Double Blind Study of 2 Doses of ZACTIMA™(ZD6474) in Combination With FOLFIRI vs FOLFIRI Alone for the Treatment of Colorectal Cancer in Patients Completed
Show 12 more trials
  1. Phase 2 Panitumumab Regimen Evaluation in Colorectal Cancer to Estimate Primary Response to Treatment Completed
  2. Phase 2 A Study to Determine the Activity of Robatumumab (SCH 717454, MK-7454) in Participants With Relapsed or Recurrent Colorectal Cancer (P04721, MK-7454-003) Completed
  3. Phase 2 A Study Evaluating the Combination of Encorafenib and Cetuximab Versus Irinotecan/Cetuximab or Infusional 5-fluorouracil (5-FU)/Folinic Acid (FA)/Irinotecan (FOLFIRI)/Cetuximab in Chinese Patients With BRAF V600E Mutant Metastatic Colorectal Cancer. Completed
  4. Phase 2 Regorafenib+FOLFIRI Versus Placebo+FOLFIRI as 2nd Line Tx in Metastatic Colorectal Cancer Completed
  5. Phase 2 Onvansertib in Combination With FOLFIRI and Bevacizumab for Second Line Treatment of Metastatic Colorectal Cancer Patients With a KRAS Mutation Completed
  6. Phase 2 Study Evaluating the Safety and Efficacy of FOLFIRI Plus Cetuximab or FOLFOX Plus Cetuximab as First-line Therapy in Subjects With KRAS Wild-type Metastatic Colorectal Cancer (APEC-Study) Completed
  7. Phase 2 A Study of Vismodegib (GDC-0449) in Patients Treated With Vismodegib in a Previous Genentech-sponsored Phase I or II Cancer Study Completed
  8. Phase 2 A Study of Vismodegib (GDC-0449, Hedgehog Pathway Inhibitor) With Concurrent Chemotherapy and Bevacizumab As First-Line Therapy for Metastatic Colorectal Cancer Completed
  9. Phase 2 Panitumumab Plus FOLFIRI in First-line Treatment of Metastatic Colorectal Cancer Completed
  10. Phase 2 Skin Toxicity Treatment in Metastatic Colorectal Cancer (mCRC) Patients Receiving Panitumumab + Irinotecan-based Therapy Completed
  11. Phase 1 Study of TSR-033 With an Anti-programmed Cell Death-1 Receptor (PD-1) in Participants With Advanced Solid Tumors Completed
  12. Phase 1 A Study to Find the Best Dose of BI 905711 in Combination With Chemotherapy and to Test Whether This Dose Helps People With Advanced Gastrointestinal Cancers Completed

Showing the 18 most-cited and recently-updated of 18 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Sequential cetuximab-bevacizumab vs bevacizumab-EGFR mAb shows no DDC difference in metastatic CRC
Oncology RCT
Sequential cetuximab-bevacizumab vs bevacizumab-EGFR mAb shows no DDC difference in metastatic CRC New Drug Order Doesn't Beat Old Standard
A phase III randomized controlled trial in 263 untreated, unresectable wild-type RAS/BRAF metastatic colorectal cancer patients found no dif…
A new drug order for advanced colon cancer did not improve disease control or survival compared to the standard treatment sequence.
Apr 16, 2026